Short Interest in Allarity Therapeutics, Inc. (NASDAQ:ALLR) Increases By 49.8%

Allarity Therapeutics, Inc. (NASDAQ:ALLR) was the recipient of a large increase in short interest during the month of September. As of September 30th, there was short interest totalling 141,700 shares, an increase of 49.8% from the September 15th total of 94,600 shares. Based on an average daily volume of 445,100 shares, the days-to-cover ratio is presently 0.3 days. Approximately 15.1% of the company’s shares are sold short.

Allarity Therapeutics Stock Performance

Shares of NASDAQ ALLR opened at $1.39 on Friday. The company’s 50 day moving average price is $1.11 and its 200-day moving average price is $1.13. Allarity Therapeutics has a 52-week low of $1.37 and a 52-week high of $666.00.

Allarity Therapeutics (NASDAQ:ALLR) last announced its earnings results on Monday, August 5th. The company reported ($0.11) earnings per share for the quarter. On average, analysts predict that Allarity Therapeutics will post -78.08 earnings per share for the current fiscal year.

Allarity Therapeutics Company Profile

Allarity Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme.